AM-DV-01 (Dengue mRNA vaccine)
AM-DV-01 is an advanced mRNA vaccine used to prevent severe dengue fever
Dengue outbreaks occurs in many tropical and subtropical areas and approximately 3.9 billion people live in the places at high risk of dengue fever. More than 400 million people are infected with dengue fever every year, of which 90 million develop severe dengue fever (hemorrhagic dengue fever/dengue shock syndrome), with 1-5% of death rate in average. At present, there is no safe preventive vaccine for dengue fever, and supportive therapy is generally adopted. The reason is that antibodies induced by viral antigens may not be able to effectively neutralize viral infection, but may increase the entry of viral infection into cells, causing massive viral replication (antibody-dependent enhancement, ADE), thereby causing severe dengue symptoms.
Indications and development progress
The dengue fever mRNA vaccine was exclusively licensed by Academia Sinica. It has been proven that using point mutations to replace the amino acid sites of the envelope E protein of the dengue virus can effectively reduce the ADE phenomenon and thereby prevent severe dengue fever. In addition, the proprietary cationic lipid was used to prepare the dengue fever mRNA vaccine and confirmed that the serum of mice has neutralizing antibodies against dengue virus infection and can significantly reduce the ADE phenomenon, thereby prolonged mouse survival rate.